# OncoResponse

Source: https://onco.cc/companies/oncoresponse/  
OnCo record `oncoresponse` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

OncoResponse is a Seattle biotech that mines the antibodies of patients who responded exceptionally well to immunotherapy; OR502 blocks LILRB2 to re-educate the suppressive myeloid cells in tumours.

## Summary

OncoResponse discovers antibodies from elite responders to cancer immunotherapy, working with MD Anderson Cancer Center. OR502 is a humanised antibody against LILRB2 (ILT4), an inhibitory receptor on macrophages and dendritic cells; blocking it shifts myeloid cells towards an anti-tumour state. OR502 is in a phase 1/2 trial alone and with cemiplimab in advanced solid tumours. Its earlier antibody OR2805 targets tumour-associated macrophages.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: OncoResponse, Inc.
- Tags: drug-maker
- HQ: Seattle, Washington
- Type: biotech
- Website: https://www.oncoresponse.com/

## Sources

- Official website: https://www.oncoresponse.com/

## Connected records

- drugs: [OR502](https://onco.cc/drugs/or502/)

---
JSON: https://onco.cc/api/v1/entities/oncoresponse.json